Exploring Relief Options That Go Beyond Just Surgery
You’ve tried the diets. The cardio. Maybe even the latest apps or cleanses. And yet… the scale barely budges. Or worse—it creeps up, even when you’re doing “everything right.”
If this sounds familiar, you are not failing. It’s easy to blame willpower, but the core issue is almost always biology. Your body is designed to defend a certain “weight set point” through powerful hunger and metabolic hormones.
At CornerstoneMD, we understand this struggle. We work with patients who are ready to stop fighting their biology and start working with it, safely and effectively
1. How Do GLP-1s Affect Appetite, Hunger, and Cravings?
They help you:
- Feel satisfied sooner: They slow digestion so you stay full longer without feeling deprived.
- Reduce cravings: They calm the reward pathways that drive strong sugar or carb urges.
- Support a healthier metabolism: They improve insulin sensitivity and stabilize blood sugar.
Essentially, these medications help your brain and gut communicate normally again around hunger and fullness, something many patients haven’t experienced in years.
In large clinical trials:
- Semaglutide produced an average of ~15% total body weight loss.
- Tirzepatide often led to 20% or more in medically supervised programs.
2. Why GLP-1s Are So Popular Now — And What We Know About Long-Term Safety
GLP-1s have become a major focus in weight management because they work with human biology instead of against it. Unlike older weight-loss medications, these drugs deliver meaningful and sustained results.
- Long safety record: GLP-1 medications have been used for over a decade in Type 2 Diabetes, giving them a strong and well-studied safety profile.
- Benefits beyond weight: Research shows improvements in blood pressure, cholesterol, inflammation markers, and cardiovascular health.
When used under medical supervision, as they are at CornerstoneMD Dallas, GLP-1 are considered safe for long-term use and often support overall metabolic health.
3. The Biggest Question: Will the Weight Come Back?
If you’ve ever dieted, you know the fear: What if the weight comes back?
Here’s the honest truth:
If you only take the medication and don’t address the underlying metabolic issues, weight regain is very possible. Your body’s hormonal “set point” is powerful and often tries to return you to your previous weight.
This is exactly why our approach matters.
We build your plan to help you lose fat, not muscle, because muscle is the foundation of a healthy metabolism. We support your body while the medication suppresses appetite so you can rebuild stability in your hormones, nutrition, and metabolism. The medication gives your biology a reset. Your lifestyle plan keeps it there long-term.
Our goal is to help you establish a healthier metabolic baseline before eventually transitioning to a maintenance phase that does not rely solely on medication.
Why Patients Choose CornerstoneMD Dallas 🩺
We work with patients who are tired of diets that fail. GLP-1 medications are one tool we use, but sustainable results come from combining medical oversight, individualized strategy, and ongoing support.
We offer a FREE 15-minute telehealth visit to introduce you to the weight-loss programs and options available at our clinic and to answer any initial questions.
Because sustainable weight loss isn’t about willpower—it’s about working with your biology safely and effectively.
👉 Schedule your free 15-minute telehealth visit today
References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.
U.S. Food and Drug Administration (FDA). Drug approval data for GLP-1 RAs for Type 2 Diabetes (establishes long-term safety history).
Ryan DH, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Lancet. 2016;387(10024):313-324.
Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.